Ignite Creation Date:
2025-12-24 @ 4:51 PM
Ignite Modification Date:
2025-12-27 @ 11:37 AM
Study NCT ID:
NCT05846750
Status:
RECRUITING
Last Update Posted:
2023-07-19
First Post:
2023-04-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-11-01
Start Date Type:
ACTUAL
Primary Completion Date:
2026-05-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-05-31
Completion Date Type:
ESTIMATED
First Submit Date:
2023-04-27
First Submit QC Date:
None
Study First Post Date:
2023-05-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-07-17
Last Update Post Date:
2023-07-19
Last Update Post Date Type:
ACTUAL